TrialAntimicrobial agents and chemotherapy2018

Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.

G Ralph Corey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.